TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15104556

Group type: EXPERIMENTAL
Intervention: Low dose therapy (1 mg/day oestradiol‐17 beta with 5 or 10 mg/day dydrogesterone)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High dose therapy (2 mg/day oestradiol‐17 beta with 10 or 20 mg/day dydrogesterone)
Number of subjects: 24
Study: 11023656

Group type: EXPERIMENTAL
Intervention: Drawing condition (children asked to draw true and false reminders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Question condition (children asked questions about the reminders but not to draw them)
Number of subjects: 0
Study: 9731391

Group type: EXPERIMENTAL
Intervention: Balance tests with head extended backwards (additional sensory condition)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Balance tests with attention-demanding task
Number of subjects: 48

Group type: COMPARATOR
Intervention: Balance tests without attention-demanding task
Number of subjects: 48
Study: 8273241

Group type: EXPERIMENTAL
Intervention: 2 mg intra-articular morphine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4 mg intra-articular morphine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (previous study)
Number of subjects: 50
Study: 3304381

Group type: EXPERIMENTAL
Intervention: Ketotifen, 1 mg twice daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31741136

Group type: EXPERIMENTAL
Intervention: Serum albumin level (per SD increase of 0.27 g/dL)
Number of subjects: 12833

Group type: EXPERIMENTAL
Intervention: Serum albumin level (Q4 vs. Q1)
Number of subjects: 12833

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis (per 1 g/dL increase of albumin)
Number of subjects: 12833
Study: 30138665

Group type: EXPERIMENTAL
Intervention: Colistin methanesulfonate (CMS) 2 MIU + azidothymidine (AZT) 100 mg
Number of subjects: 7
Study: 28235206

Group type: EXPERIMENTAL
Intervention: 1,000 mg omega-3 fatty acids from flaxseed oil containing 400 mg α-linolenic acid, twice a day for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo, twice a day for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1,000 mg omega-3 fatty acids from flaxseed oil
Number of subjects: 60
Study: 26356057

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Indomethacin per rectum and opiate analgesic intramuscularly
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: TEA in high risk patients
Number of subjects: 195
Study: 23924660

Group type: EXPERIMENTAL
Intervention: Ribavirin dosage reduction (n = 249)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy (n = 251)
Number of subjects: 500

Group type: COMPARATOR
Intervention: No anemia (n = 187)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy (n = 295)
Number of subjects: 500

Group type: COMPARATOR
Intervention: No erythropoietin therapy (n = 392)
Number of subjects: 500
Study: 21918294

Group type: EXPERIMENTAL
Intervention: Chemical irritation of the esophagus with acid and capsaicin perfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo perfusions
Number of subjects: 0
Study: 18597068

Group type: COMPARATOR
Intervention: 2003 recommended American Diabetes Association diet (ADA)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Low glycaemic index (LGI) diet
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Modified Mediterranean diet (MMD)
Number of subjects: 259
Study: 16557151

Group type: EXPERIMENTAL
Intervention: Pflex/LTV (low tidal volume 5-8 mL/kg PBW, PEEP set at Pflex + 2 cm H2O)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (tidal volume 9-11 mL/kg PBW, PEEP >= 5 cm H2O)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control
Number of subjects: 103
Study: 15121371

Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo and laser treatment
Number of subjects: 46
Study: 11336589

Group type: EXPERIMENTAL
Intervention: Antimicrobial agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New antimicrobial compounds
Number of subjects: 0
Study: 9805220

Group type: EXPERIMENTAL
Intervention: 100 ml of red wine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 100 ml of malt whisky
Number of subjects: 9

Group type: COMPARATOR
Intervention: Unmatured 'new make' spirit
Number of subjects: 9
Study: 8301543

Group type: COMPARATOR
Intervention: 0 mg/70 kg morphine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2.5 mg/70 kg morphine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5.0 mg/70 kg morphine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg morphine
Number of subjects: 12
Study: 2899239

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (28 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (14 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral frusemide (20 mg)
Number of subjects: 0
Study: 29059442

Group type: EXPERIMENTAL
Intervention: Financial incentives ($15-$35 rewards for brief smoking abstinence)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group ($10 at each assessment regardless of abstinence)
Number of subjects: 50
Study: 29276227

Group type: EXPERIMENTAL
Intervention: Constant Current (CC) system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Constant Voltage (CV) system
Number of subjects: 20
Study: 26599247

Group type: EXPERIMENTAL
Intervention: ReSure Sealant
Number of subjects: 1
Study: 23181989

Group type: EXPERIMENTAL
Intervention: Chewing forty times per portion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Chewing fifteen times per portion
Number of subjects: 21
Study: 22010808

Group type: EXPERIMENTAL
Intervention: CPOL intervention (N = 1,695)
Number of subjects: 3311

Group type: COMPARATOR
Intervention: Control condition (N = 1,616)
Number of subjects: 3311

Group type: EXPERIMENTAL
Intervention: Both CPOL intervention and control
Number of subjects: 3311
Study: 18297290

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX-A) injections at different doses
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 16847080

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 14564313

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg/day in addition to HMG-CoA reductase inhibitor
Number of subjects: 15000

Group type: COMPARATOR
Intervention: HMG-CoA reductase inhibitor
Number of subjects: 15000
Study: 11091245

Group type: EXPERIMENTAL
Intervention: Perioperative blood transfusion with subsequent development of postoperative infectious complications
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Perioperative blood transfusion without subsequent infection
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Postoperative infectious complications without preceding transfusion
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Combination of blood transfusion and subsequent development of infection
Number of subjects: 740

Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 740

Group type: COMPARATOR
Intervention: Transfused patients
Number of subjects: 740
Study: 9069566

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 6847

Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetes mellitus (NIDDM)
Number of subjects: 6847

Group type: COMPARATOR
Intervention: Age association with IGT
Number of subjects: 6847

Group type: COMPARATOR
Intervention: Age association with NIDDM
Number of subjects: 6847

Group type: COMPARATOR
Intervention: BMI association with IGT
Number of subjects: 6847

Group type: COMPARATOR
Intervention: BMI association with NIDDM
Number of subjects: 6847

Group type: COMPARATOR
Intervention: Height association with NIDDM
Number of subjects: 6847

Group type: COMPARATOR
Intervention: Logistic regression analysis
Number of subjects: 6847
Study: 8349904

Group type: EXPERIMENTAL
Intervention: Pre-education (written explanation of the need for full body skin examination)
Number of subjects: 286

Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 286
Study: 3568020

Group type: EXPERIMENTAL
Intervention: Mass screening for breast cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 0
Study: 31367914

Group type: EXPERIMENTAL
Intervention: F-100
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: F-100D
Number of subjects: 153

Group type: COMPARATOR
Intervention: IF
Number of subjects: 153
Study: 29532297

Group type: EXPERIMENTAL
Intervention: Automated notification system for finalized TPADs via email
Number of subjects: 253

Group type: COMPARATOR
Intervention: Usual care (no automated notification)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Automated notification system for finalized TPADs via email (sub-group analysis)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Usual care (no automated notification) (sub-group analysis)
Number of subjects: 253
Study: 26028361

Group type: EXPERIMENTAL
Intervention: 2.4 g amino acids/(kg·d) plus 2 g lipids/(kg·d)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 3.6 g amino acids/(kg·d) plus 2 g lipids/(kg·d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 2.4 g amino acids/(kg·d) (control group)
Number of subjects: 28
Study: 24448121

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 22512461

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus systemic amoxicillin + metronidazole (SMA)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus periodontal surgery (SURG)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus local tetracycline delivery (LTC)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) plus no adjunctive treatment
Number of subjects: 187
Study: 19680275

Group type: EXPERIMENTAL
Intervention: 25-gauge MIVS
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 23-gauge MIVS
Number of subjects: 85
Study: 17970791

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Colposuspension
Number of subjects: 344
Study: 15840990

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12809960

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg TID
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/d
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg TID with Fluvastatin 80 mg/d
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 11034935

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 19768
Study: 8674343

Group type: EXPERIMENTAL
Intervention: Hypothermic group (32 degrees C for 24 hrs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normothermic treatment group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid nitrite and nitrate concentrations
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cerebral blood flow
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Arterio‐jugular oxygen content difference
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plasma nitrite and nitrate concentrations
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Injury Severity Score
Number of subjects: 15
Study: 1797999

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: White-coat hypertension
Number of subjects: 0
Study: 6409627

Group type: EXPERIMENTAL
Intervention: Low-fat diet (25% of energy)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-fat diet (45% of energy)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diet rich in polyunsaturated fatty acids
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diet high in saturated fatty acids
Number of subjects: 12
Study: 30608337

Group type: EXPERIMENTAL
Intervention: Maggot therapy (MT)
Number of subjects: 50
Study: 28067068

Group type: EXPERIMENTAL
Intervention: Special examination gown + nature-based sounds
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no special gown or sounds)
Number of subjects: 120
Study: 27253669

Group type: EXPERIMENTAL
Intervention: Continuous oral contraceptive pill (OCP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined (OCP + Intensive lifestyle intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 24297663

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg/day
Number of subjects: 18
Study: 23207332

Group type: EXPERIMENTAL
Intervention: Peg-IFNa-2a for 72 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Peg-IFNa-2a for 48 weeks
Number of subjects: 86
Study: 20709087

Group type: EXPERIMENTAL
Intervention: 800ml of paper filtered coffee daily for 5 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 38
Study: 17383912

Group type: COMPARATOR
Intervention: Normal saline drops before and after surgery (Group A)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Normal saline drops before and tetracaine 1% drops after surgery (Group B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tetracaine 1% drops before and after surgery (Group C)
Number of subjects: 88
Study: 16350716

Group type: EXPERIMENTAL
Intervention: Orlistat 3 x 120mg a day with a 1000-1200 kcal/day balanced diet and regular physical exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy women, mean age 53.5 ± 5.4 yrs, BMI 24.1 ± 2.2 kg/m2)
Number of subjects: 20
Study: 12062881

Group type: EXPERIMENTAL
Intervention: Low-dose haloperidol (mean dose 5.0 mg at 6 months)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Risperidone (mean dose 6.0 mg at 6 months)
Number of subjects: 62
Study: 10552264

Group type: EXPERIMENTAL
Intervention: Face skin cooling (FaC)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combined cooling (CoC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cool air breathing (CAB)
Number of subjects: 7
Study: 9088582

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolmitriptan single dose 10 mg
Number of subjects: 12
Study: 1300759

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (15% decrease in total caloricity, 30% reduction in fat, 9% reduction in carbohydrates)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 108
Study: 3889100

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg twice daily
Number of subjects: 301
Study: 29671353

Group type: EXPERIMENTAL
Intervention: Hormonal contraception after 3 months (T2)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Seasonal variations in HRQOL
Number of subjects: 431
Study: 27552275

Group type: EXPERIMENTAL
Intervention: Immediate offer of genetic counseling
Number of subjects: 102

Group type: COMPARATOR
Intervention: Mailed brochure on how to obtain counseling
Number of subjects: 102
Study: 24518169

Group type: EXPERIMENTAL
Intervention: Early insulin treatment
Number of subjects: 283
Study: 22406658

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Propranolol No-Shock Expectation
Number of subjects: 55
Study: 19812926

Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate tissue adhesive for final layer closure of the skin (44 children)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-absorbable one-on-one single skin sutures (46 children)
Number of subjects: 90
Study: 18180864

Group type: EXPERIMENTAL
Intervention: Insulin glargine added to current oral antidiabetic drugs (OAD) regimen
Number of subjects: 55

Group type: COMPARATOR
Intervention: Increased dosage of oral antidiabetic drugs (OAD)
Number of subjects: 55
Study: 15858073

Group type: EXPERIMENTAL
Intervention: Phonics treatment package
Number of subjects: 0
Study: 12650495

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block with 5 mL 0.5% bupivacaine with epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piroxicam patch (48 mg) applied to each shoulder
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 60
Study: 10792383

Group type: COMPARATOR
Intervention: HAART (n = 6)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HAART plus low dose rIL-2 (1000 000 U/daily) (n = 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HAART plus rIL-2 after granulocyte colony-stimulating factor (n = 8)
Number of subjects: 22
Study: 8680492

Group type: EXPERIMENTAL
Intervention: Jet injector for morphine (8 mg, 5 mg if weight ≤ 65 kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Needle and syringe for morphine (8 mg, 5 mg if weight ≤ 65 kg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Jet injector for heparin (3500 U every 8 hours for 5 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Needle and syringe for heparin (3500 U every 8 hours for 5 days)
Number of subjects: 59
Study: 1847278

Group type: COMPARATOR
Intervention: Pancuronium (100 micrograms/kg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pipecuronium (80 micrograms/kg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg/kg) plus Pancuronium (100 micrograms/kg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg/kg) plus Pipecuronium (80 micrograms/kg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: All groups (pancuronium and pipecuronium)
Number of subjects: 52
Study: 30327777

Group type: EXPERIMENTAL
Intervention: Food insecure households
Number of subjects: 696

Group type: COMPARATOR
Intervention: Food secure households
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Age range 30-39
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Women with 10 or more years age difference with their husband
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Women with high decision-making power
Number of subjects: 696
Study: 26890244

Group type: EXPERIMENTAL
Intervention: Live High-Train Low (LHTL) training (n=10)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo training (n=6)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isovolumic hemodilution
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Maximal exercise (both groups)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Post-exercise after isovolumic hemodilution
Number of subjects: 16
Study: 24759327

Group type: EXPERIMENTAL
Intervention: Melimine-coated lenses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncoated lenses
Number of subjects: 0
Study: 23270288

Group type: EXPERIMENTAL
Intervention: Fränkel II appliance treatment for 1 year 11 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (untreated subjects in Class II division 1)
Number of subjects: 25
Study: 20231536

Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: telmisartan
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: combination of ramipril and telmisartan
Number of subjects: 1549

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1549
Study: 18318974

Group type: EXPERIMENTAL
Intervention: Expert Patients Programme self-management course
Number of subjects: 629
Study: 15883418

Group type: EXPERIMENTAL
Intervention: Ad libitum low-glycemic load diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional low-fat diet
Number of subjects: 23
Study: 12645641

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical approach (CABG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive approach including PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New devices (thrombectomy devices, drug-eluting stents)
Number of subjects: 0
Study: 10484395

Group type: EXPERIMENTAL
Intervention: Active rectal distension
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rectal distension
Number of subjects: 10
Study: 9139277

Group type: COMPARATOR
Intervention: Responsive patients (on one or two drugs)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Resistant patients (on three or more drugs)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Patients with essential hypertension resistant to treatment
Number of subjects: 299

Group type: COMPARATOR
Intervention: Patients with essential hypertension responsive to antihypertensive treatment
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Patients with essential hypertension
Number of subjects: 299
Study: 1897471

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Stimulation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study: 6315911

Group type: EXPERIMENTAL
Intervention: Marijuana (20 mg doses of delta‐9 tetrahydrocannabinol)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 31542292

Group type: EXPERIMENTAL
Intervention: Early combination therapy with vildagliptin (50 mg twice daily) and metformin (stable daily dose of 1000 mg, 1500 mg, or 2000 mg)
Number of subjects: 2001

Group type: COMPARATOR
Intervention: Initial metformin monotherapy (stable daily dose of 1000 mg, 1500 mg, or 2000 mg) and placebo twice daily
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: Early combination therapy with vildagliptin and metformin
Number of subjects: 2001

Group type: COMPARATOR
Intervention: Initial metformin monotherapy
Number of subjects: 2001